Hospital reports 13 percent increase in HCAHPS after deploying leader rounding and care call technology SAN JOSE, Calif. January 4, 2018 –(BUSINESS WIRE)– Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that Hunt Regional Medical Center has improved patient engagement and satisfaction by standardizing nurse leader rounding and […]
SPRINGFIELD, IL., and SALT LAKE CITY, January 3, 2018 – Health Catalyst, a technology leader in healthcare analytics, decision support and outcomes improvement, announced a multi-year agreement with Hospital Sisters Health System to implement the Health Catalyst Data Operating System (DOS™). Hospital Sisters Health System (HSHS) is a multi-institutional health care system that cares for […]
$2.8 million contract caps record year of federal bookings for Vocera SAN JOSE, Calif. January 3, 2018 –(BUSINESS WIRE)– Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, announced today that U.S. Army Regional Health Command-Pacific (RHC-P) is expanding Vocera technology at three military facilities. This $2.8 million contract completes a […]
Coordinated care network co-develops opioid risk-prediction tool; adopts Data Operating System PORTLAND, OR. and SALT LAKE CITY – December 19, 2017 – In an effort to further enhance quality and lower the cost of health care, Health Share of Oregon and Health Catalyst have expanded their partnership through the implementation of a data-first application platform […]
Company Expects to Complete Submission for Fast Track Designated Medicine by Year-End 2017 DUBLIN–(BUSINESS WIRE)–Aug. 21, 2017– Alkermes plc (NASDAQ:ALKS) today announced the initiation of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), seeking marketing approval of ALKS 5461, a once-daily, oral investigational medicine with a […]
Once-Daily, Oral Product Candidate Demonstrated Antipsychotic Efficacy Statistically Superior to Placebo and Similar to Olanzapine in ENLIGHTEN-1 Study Management to Hold Conference Call Today at 4:30 p.m. ET DUBLIN–(BUSINESS WIRE)–Jun. 29, 2017– Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from ENLIGHTEN-1, the first of two key phase 3 studies in the ENLIGHTEN […]
Phase 3b Study Designed to Further Evaluate ALKS 5461’s Potential Benefits on Mood Domains Regulated by Endogenous Opioid Modulation Company Reiterates Plans to Submit New Drug Application to FDA by Year-End 2017 DUBLIN–(BUSINESS WIRE)–Jun. 12, 2017– Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a […]
Designed to Assess Weight Gain Profile of Olanzapine Compared to ALKS 3831 in Patients Diagnosed With Schizophrenia, Schizophreniform or Bipolar I Disorder Who Are Early in Their Illness Supportive Study in the ENLIGHTEN Clinical Development Program for ALKS 3831, an Investigational, Novel, Once-Daily, Oral Atypical Antipsychotic for the Treatment of Schizophrenia DUBLIN–(BUSINESS WIRE)–Jun. 8, 2017– […]
First and Only Long-Acting Atypical Antipsychotic With Two-Month Dosing Option Approval Expands ARISTADA’s Product Offerings to Include Once-Monthly, Once-Every-Six-Weeks and Once-Every-Two-Months Dosing Durations DUBLIN–(BUSINESS WIRE)–Jun. 6, 2017– Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. […]
Anonymous donation will help create safe, healing space for emergency patients RALEIGH, N.C. February 13, 2017 – UNC REX Healthcare plans to build a new holding area for behavioral health patients who seek treatment in the emergency department, thanks to an anonymous donor who is contributing $2.5 million. The separate behavioral health zone will include […]